43
Participants
Start Date
June 21, 2019
Primary Completion Date
October 3, 2022
Study Completion Date
October 3, 2022
NKTR-214 (Cohort A)
NKTR-214 will be administered intravenously every 3 weeks for up to 2 years
Nivolumab (Cohort A, B and C)
Nivolumab will be administered intravenously every 3 weeks for up to 2 years to cohort A, every 4 weeks for up to 2 years for cohort B and C.
Stereotactic body radiation therapy (SBRT) (Cohort B)
Radiation therapy will be administered at 30 - 50 Gy in 1 - 5 doses, starting on Day 1 or 2 of Cycle 1
CDX-301 (Cohort B and C)
CDX-301 will be subcutaneously once a day for 5 days for cohort B. CDX-301 will be subcutaneously once a day for 10 days of immune-priming lead-in for cohort C.
Poly-ICLC (Cohort B)
Poly-ICLC will be administered intramuscularly twice weekly for 3 weeks starting on Day 1 of Cycle 1
INO-5151 (Cohort C)
INO-5151 will be administered intramuscularly on Day 8 of the Immune-priming Lead-in, and on day 1 of Cycle 1, 2 and 3, then every 12 weeks thereafter
Cellectra 2000
Electroporation device
Mount Sinai, New York
Memorial Sloan Kettering Cancer Center, New York
The University of Texas MD Anderson Cancer Center, Houston
Angeles Clinic, Los Angeles
University of California San Francisco, San Francisco
Oregon Health & Science University, Portland
Bristol-Myers Squibb
INDUSTRY
Celldex Therapeutics
INDUSTRY
Cancer Research Institute, New York City
OTHER
Inovio Pharmaceuticals
INDUSTRY
Oncovir, Inc.
INDUSTRY
Parker Institute for Cancer Immunotherapy
OTHER